Exelixis
EXEL
#1709
Rank
โ‚ฌ10.76 B
Marketcap
42,81ย โ‚ฌ
Share price
-0.58%
Change (1 day)
7.62%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Earnings for Exelixis (EXEL)

Earnings in 2026 (TTM): โ‚ฌ0.85 Billion

According to Exelixis's latest financial reports the company's current earnings are โ‚ฌ2.37 Billion. In 2025 the company made an earning of โ‚ฌ0.80 Billion, an increase over its 2024 earnings that were of โ‚ฌ0.58 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Exelixis from 2000 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) โ‚ฌ0.85 B5.99%
2025 โ‚ฌ0.80 B38.08%
2024 โ‚ฌ0.58 B164.69%
2023 โ‚ฌ0.22 B9.89%
2022 โ‚ฌ0.20 B-20.33%
2021 โ‚ฌ0.25 B124.82%
2020 โ‚ฌ0.11 B-67.14%
2019 โ‚ฌ0.34 B-11.94%
2018 โ‚ฌ0.38 B185.09%
2017 โ‚ฌ0.13 B-325.82%
2016 -โ‚ฌ60.33 Million-58.12%
2015 -โ‚ฌ0.15 Billion-37.61%
2014 -โ‚ฌ0.24 Billion9.75%
2013 -โ‚ฌ0.22 Billion65.96%
2012 -โ‚ฌ0.13 Billion-291.63%
2011 โ‚ฌ66.13 M-195.59%
2010 -โ‚ฌ69.19 Million-42.17%
2009 -โ‚ฌ0.12 Billion-18.98%
2008 -โ‚ฌ0.15 Billion-6.99%
2007 -โ‚ฌ0.16 Billion46.3%
2006 -โ‚ฌ0.11 Billion33.25%
2005 -โ‚ฌ81.45 Million-30.92%
2004 -โ‚ฌ0.12 Billion44.29%
2003 -โ‚ฌ81.71 Million12.86%
2002 -โ‚ฌ72.4 Million22.79%
2001 -โ‚ฌ58.97 Million60.14%
2000 -โ‚ฌ36.82 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Johnson & Johnson
JNJ
โ‚ฌ22.31 B 2,489.61%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
โ‚ฌ9.09 B 955.72%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
โ‚ฌ7.80 B 805.80%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
โ‚ฌ6.57 B 663.41%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
โ‚ฌ11.29 B 1,211.00%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚ฌ8.24 B 856.64%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
โ‚ฌ8.59 B 897.95%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
-โ‚ฌ27.97 Million-103.25%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-โ‚ฌ24.95 Million-102.89%๐Ÿ‡บ๐Ÿ‡ธ USA